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Abstract 
 
Background: We examined the expression of nonhomologous end-joining (NHEJ) 
proteins by breast cancer cells in patients with or without ipsilateral breast tumor 
recurrence (IBTR) after breast-conserving therapy. We also investigated whether there 
was a difference of NHEJ-related protein expression by tumor cells between two types of 
IBTR, i.e., true recurrence (TR) with regrowth from the tumor bed or development of a 
new primary tumor (NP).  
 
Patients and Methods: The original cohort was 560 breast cancer patients who received 
breast-conserving therapy between February 1995 and March 2006, including 520 
patients without IBTR and 40 patients with IBTR. Propensity score matching was 
employed to select 40 trios (120 patients) consisting of 1 patient with IBTR and 2 patients 
without IBTR. Immunohistochemical examination of proteins related to NHEJ was 
performed in surgical specimens. 
 
Results: The 40 patients with IBTR included 22 patients who developed TR and 18 who 
had NP. The 15-year overall survival rate was 85.9% for patients with NP and 95.5% for 
those with TR, while it was 96.5% for patients without IBTR. Patients with high XRCC4 
expression in tumor cells had significantly higher IBTR rates than those with low XRCC4 
expression (P<0.001). The frequency of TR was significantly higher in patients with high 
expression of XRCC4 than in those with low XRCC4 expression ( p < 0.001). XRCC4 
expression by tumor cells was not significantly related to development of NP.  
 
Conclusion: IBTR due to TR may be related to low radiosensitivity of tumor cells, 
possibly related to high XRCC4 expression. 
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Hintergrund: Wir untersuchten die Tumorexpression von nicht-homologen 
endverknüpften Proteinen (NHEJ) in Patienten mit oder ohne ipsilateralen 
Brustkrebszrezidiven (IBTR) nach brusterhaltenden Therapieverfahren. Weiterhin 
untersuchten wir, ob die Expression NHEJ verwandter Proteine bei den beiden IBTR 
Typen, d.h. echter Rezidive mit Nachwachsen vom Tumorbett oder Entwicklung neuer 
Primärtumore unterschiedlich ist.  
 
Patienten und Methoden: Die ursprüngliche Gruppe umfasste 560 zwischen Februar 1995 
und März 2006 mit brusterhaltenden Therapieverfahren behandelte Brustkrebspatienten, 
einschließlich 520 Patienten ohne IBTR und 40 Patienten mit IBTR. Propensity score 
matching wurde eingesetzt, um 40 Trios (120 Patienten) aus 1 Patient mit IBTR und 2 
Patienten ohne IBTR auszuwählen. Immunhistochemische Untersuchungen der NHEJ-
verwandten Proteine wurden an Biopsieproben durchgeführt. 
 
Ergebnisse: Die 40 Patienten mit IBTR umfassten 22 Patienten mit echten Rezidiven und 
18 die einen neuen Primärtumor entwickelten. Die 15-Jahres Gesamtüberlebensrate 
betrug 85.9% für Patienten mit einem neuen Primärtumor und 95.5% für Patienten mit 
echten Rezidiven, während sie für Patienten ohne IBTR 96.5% war. Patienten mit einer 
starken XRCC4 Expression durch die Tumorzellen hatten eine signifikant höhere IBTR 
Rate als diejenigen mit geringer XRCC4 Expression (p < 0,001). Die Häufigkeit echter 
Rezidive war bei Patienten mit erhöhter XRCC4 Expression höher als bei Patienten mit 
geringer XRCC4 Expression (21/64 Patienten versus 1/56 Patienten). Demgegenüber 
hatte die XRCC4 Expression keine wesentliche Beziehung zur Entwicklung eines neuen 
Primärtumors. 
 
Schlussfolgerung: Durch echte Rezidive hervorgerufene IBTR könnte mit der geringen 
Strahlenempfindlichkeit der Tumorzellen und möglicherweise der hohen XRCC4 
Expression in Verbindung stehen. 
 
 
Stichwort: Strahlentherapie, XRCC4, ipsilateral Brusttumorrezidiv, neuer primärer 





































































Breast-conserving surgery and postoperative whole breast irradiation are recommended 
for stage I and II early breast cancer, since whole breast irradiation decreases the risk of 
ipsilateral breast tumor recurrence (IBTR) after such surgery [1]. When IBTR occurs, the 
patient’s quality of life is affected by the need for mastectomy and chemotherapy. In 
addition, IBTR is one of the risk factors for distant metastasis and is associated with a 
higher risk of breast cancer death [2]. Therefore, prediction and prevention of IBTR could 
improve the prognosis of breast cancer. Several studies have identified 
clinicopathological factors showing a relationship with IBTR, such as young age, tumor 
size, genetic predisposition, lymph node metastasis, positive surgical margin, nuclear 
grade, and no postoperative radiation therapy [1–5]. However, the results have not been 
consistent, and further research into relevant biological factors based on the molecular 
mechanism of radiosensitivity is required. 
IBTR can be divided into two types, which are true recurrence (TR) and development 
of a new primary tumor (NP) [6]. TR is defined as tumor regrowth because of incomplete 
surgical resection or resistance to postoperative irradiation, while NP is classified as a de 
novo malignancy arising in the residual breast. It has been reported that TR and NP show 
no differences in terms of tumor histology at diagnosis or recurrence, although TR 
manifests earlier [7], but there have been no investigations of radiosensitivity.  
 
The ability of cells to repair of DNA damage influences radiosensitivity [8], with 
nonhomologous end-joining (NHEJ) being considered important as the main mechanism 
involved in repairing DNA double-stranded breaks [9]. In the NHEJ process, Ku70/80 
heterodimer recognizes the ends of double-stranded DNA and recruits the DNA-PK 
catalytic subunit (DNA-PKcs), after which the two DNA ends are ligated by the XRCC 4 
(X-ray repair cross-complementing group 4)-Ligase IV-XLF complex. XRCC4 associates 
with and activates DNA ligase IV, which joins two DNA ends in the final step of NHEJ 
[10], and XRCC4 is required for stabilization and nuclear localization of DNA ligase IV 
[11, 12]. XRCC4 also interacts with other proteins, such as polynucleotide 
kinase/phosphatase (PNKP), aprataxin, and aprataxin-PNKP-like factor (APLF), which 
are involved in processing DNA ends during NHEJ. Thus, XRCC4 has physical and 
functional interactions with many proteins and might act as a regulatory molecule for 
NHEJ [13]. Low expression of factors involved in repair of DNA damage is known to 
result in greater radiosensitivity [14], and Askmalm et al. reported that expression of 


































































breast cancer [15]. 
 
Accordingly, this study was performed to investigate the association between IBTR and 
NHEJ-related protein expression by tumor cells, as well as to determine whether tumor 



































































Patients and Methods 
[Patients] 
This retrospective study was approved by the ethics committee of Sapporo Medical 
University Hospital (No. 282–248) and consent to participation was obtained from either 
the patient or a family member. Surgical specimens were available for a total of 560 
patients with early breast cancer who underwent breast-conserving surgery at our 
institution from February 1995 to March 2006 and received postoperative radiation 
therapy. Table 1 lists the characteristics of the patients. 
 
[Treatment] 
After breast-conserving surgery, whole breast irradiation was planned by employing 
three-dimensional treatment. From February 1995 to December 1999, 147 patients were 
treated by using 60Cog-rays, while 413 patients were treated with 4 MV X-rays from 
January 2001 to March 2006. The median dose was 50 Gy (range, 48–60 Gy), and 
treatment was delivered in 1.8–2 Gy fractions. In 127 patients with positive surgical 
margins, 10 Gy of electron beam irradiation was added to the tumor bed after completing 
whole breast irradiation. In addition, 80 patients with axillary lymph node metastasis 
received 48–50 Gy to the ipsilateral supraclavicular fossa. Hormone therapy was given to 
405 patients and 108 patients received chemotherapy (Table 1). 
 
[Ipsilateral Breast Tumor Recurrence] 
IBTR was classified as TR and NP on the basis of pathological information and location 
[6]. TR was defined as a recurrent tumor with the same histopathological features as the 
primary lesion or as a tumor arising from the same site as the primary close to the surgical 
margin. NP was defined as a tumor arising at a different site from the primary lesion 
and/or a tumor that was pathologically different from the primary. Classification was done 
in consultation with the surgeons who performed breast-conserving surgery. 
 
[Immunohistochemical staining] 
Immunohistochemical staining was carried out by the method described previously [15]. 
Formalin-fixed, paraffin-embedded surgical specimens were cut into sections 3 µm thick 
and mounted on glass slides, followed by staining with Ku70 monoclonal antibody (MC-
351, clone N3H10, Kamiya Biochemical Company, Tukwila, WA, USA) and XRCC4 
rabbit polyclonal antiserum [17]. The number of tumor cells in the most highly stained 
area was counted at a high power (X400), and the number of cells with Ku70 or XRCC4 


































































to calculate the percentages of cells positive for Ku70 or XRCC4 expression. Assessment 
of immunohistochemical staining was done independently by two researchers. Receiver 
operating characteristics (ROC) analysis was employed to determine appropriate cut-off 
levels for expression of XRCC4 (74%) and Ku70 (94%). 
 
[Statistical analysis] 
Clinical and tumor characteristics were compared between patients with TR or NP by 
Fisher’s exact test. Overall survival (OS), disease-free survival, and IBTR-free survival 
were calculated from the date of surgery by the Kaplan-Meier method, and differences of 
survival were analyzed by the log-rank test. The Cox proportional hazards model was 
used for univariate and multivariate analyses. All p values were two-sided and 
significance was accepted at p < 0.05. Statistical analysis was carried out with EZR 





































































[Original cohort]  
After the 560 patients were followed for a median of 150 months, IBTR occurred as the 
first recurrence in 40 patients (7.1%). The 5-year, 10-year, and 15-year cumulative IBTR-
free rates were 98.9%, 94.8%, and 91.0%, respectively (Fig. 1A). The 40 patients with 
IBTR were classified into 22 patients with TR and 18 patients with NP. There were no 
differences of clinical, pathological, and treatment factors between the TR and NP groups 
(Table 2). 
The IBTR-free survival rate showed no significant difference between the TR and NP 
groups (Fig. 1B, p = 0.359). Median IBTR-free survival was 106 months (range, 22–228 
months) in the TR group and 83 months (range, 22–167 months) in the NP group. The 
15-year OS rate was 85.9% in the NP group, 95.5% in the TR group, and 96.5% in patients 
without IBTR (Fig. 1C), with no significant differences among these three groups (p = 
0.182).  
In the TR group (n = 22), repeat lumpectomy was performed in 7 patients and 
mastectomy was done in 15 patients. Also, 17 patients received endocrine therapy and 
chemotherapy was given to 6 patients as salvage therapy. In the NP group (n = 18), repeat 
lumpectomy was done in 5 patients and 13 patients received mastectomy. In addition, 15 
patients were given endocrine therapy and chemotherapy was delivered to 4 patients as 
salvage therapy. 
Univariate and multivariate analyses were performed to assess the relations between 
IBTR and clinical, pathological, or treatment factors (Table 3). As a result, estrogen 
receptor status was the only significant determinant of IBTR according to univariate 
analysis (p < 0.001) and multivariate analysis (p < 0.001). 
 
[Propensity-score matched cohort] 
To evaluate the association between expression of NHEJ-related proteins (XRCC4 and 
Ku70) by tumor cells and IBTR, we generated a propensity-score matched cohort 
containing IBTR patients and non-IBTR patients at a 1:2 ratio, since there were nearly 13 
times more patients without IBTR in the original cohort. Table 4 shows the distribution 
of various factors in the IBTR patients and control (non-IBTR) patients. By matching 
propensity scores, we obtained 40 well-balanced trios (total, 120 patients) from the 
original cohort. In the matched cohort, the IBTR and non-IBTR patients did not show 
significant differences of any of the factors investigated (age, histology, lymphovascular 


































































supraclavicular node irradiation). 
 
[Expression of NHEJ-related proteins in the matched cohort] 
We also examined the expression of NHEJ-related proteins by breast cancer cells. Both 
normal epithelial cells and breast cancer cells showed diffuse nuclear staining by Ku70 
and XRCC4, with no cytoplasmic or membrane immunoreactivity (Fig. 2A). Figure 2 
also shows box plots of the distribution of XRCC4 expression (Fig. 2B) and Ku70 
expression (Fig. 2C) in the non-IBTR, TR, and NP groups. The mean level of XRCC4 
expression was significantly higher in the TR group than in the non-IBTR group (p < 
0.001), whereas there was no significant difference between the NP and non-IBTR groups 
(p = 0.472). There were no differences of Ku70 expression among the non-IBTR, TR, and 
NP groups.   
  
[Relation between IBTR and NHEJ-related protein expression in the matched cohort] 
There was a significantly higher frequency of IBTR in patients with high XRCC4 
expression than in those with low XRCC4 expression (p < 0.001, Fig. 3A). On the other 
hand, there was no significant difference in the frequency of IBTR between patients with 
low and high Ku70 expression (p = 0.462, Fig. 3B). 
Next, we investigated whether there was a difference of XRCC4 expression between 
the TR and NP groups. We found that TR was significantly more frequent in patients with 
high levels of XRCC4 expression by tumor cells than in those with low XRCC4 
expression (Fig. 3C). In fact, TR only occurred in 1 out of 56 patients with low XRCC4 
expression versus 21 out of 64 patients with high XRCC4 expression (Fig. 3C). In contrast, 
the level of XRCC4 expression by tumor cells was not significantly related to NP (Fig. 
3D). According to both univariate and multivariate analysis, only XRCC4 expression was 
significantly associated with IBTR among various biological, clinical, and treatment-






































































  This study showed that IBTR was the initial mode of recurrence in 40 out of 560 
patients (7.1%) after a median follow-up period of 150 months. The 5-year, 10-year, and 
15-year cumulative IBTR-free rates were 98.9%, 94.8%, and 91.0%, respectively, 
suggesting that IBTR could still occur more than 15 years after initial treatment (Fig. 1A). 
Jobsen et al. investigated the pattern of IBTR over time and reported 2 peaks, with the 
first peak at approximately 5 years and the second (much higher) peak at approximately 
12 years [19]. Our findings seem to be reasonable in comparison with their report. 
  There is no standard method for classifying IBTR as TR or NP, but many studies have 
based this classification on tumor location and histology [4, 7], so we also used these 
criteria. Accordingly, the 40 patients with IBTR were classified into 22 with TR and 18 
with NP. Yoshida et al. used the same criteria for classification of TR and NP, reporting 
that 60 patients with IBTR were classified into 52 who had TR and 8 who had NP [4]. In 
their study, 27 of the 60 IBTR patients did not receive postoperative radiotherapy, which 
could explain the higher frequency of TR than in our series. 
   We found no significant difference of the IBTR-free survival rate between the TR and 
NP groups (Fig. 1B). The median time to recurrence was 8.9 years in the TR group and 
7.0 years in the NP group. Also, the 15-year OS rate was 85.9% in the NP group, 95.5% 
in the TR group, and 96.5% in patients without IBTR (Fig. 1C). Previous study reported 
that recurrence was significantly more rapid in patients with TR than NP [7]. In this study, 
more TR patients than NP patients received endocrine therapy. However, there was no 
difference of endocrine therapy between our TR and NP groups (Table 2), which could 
explain the longer time to IBTR, especially TR. 
  Among various clinical, pathological, and treatment factors that we investigated, 
estrogen receptor status was the only significant determinant of IBTR in both univariate 
and multivariate analysis (Table 2). However, Wapnir et al. reported that ER negativity 
was not a predictor of IBTR [2]. In Wapnir’s study, endocrine therapy was administered 
to 1557 of 2091 ER-positive patients (74.5%). In contrast, 338 of 374 ER-positive patients 
(90.4%) received endocrine therapy in our study (supplementary table 1), which could 
help to explain the different results. Also, in several reports, radiotherapy reduces the rate 
of IBTR with ER positive patients [1,20]. Other risk factors for early local recurrence that 
have been reported include a young age at diagnosis (< 40 years), larger tumor, multifocal 
disease, axillary node involvement, extracapsular tumor extension, positive margin, high 
nuclear grade, definite positive lymphovascular invasion, HER-2 overexpression, and 


































































clinical or therapeutic predictors of IBTR after radiotherapy. 
 We also examined the expression of two NHEJ-related proteins, XRCC4 and Ku70, by 
breast cancer cells (Fig. 2A). To evaluate the association between expression of these 
proteins by tumor cells and IBTR, we generated a propensity-score matched cohort.  We 
found that the frequency of IBTR was significantly higher in patients with higher tumor 
cell expression of XRCC4 than in patients with low XRCC4 expression (Fig. 3A), 
suggesting that XRCC4 might be a prognostic factor for IBTR. XRCC4 is one of the 
essential players in NHEJ-mediated DSB repair and V(D)J recombination [12]. We 
previously reported the detection of XRCC4 expression in paraffin-embedded tumor 
tissues, and showed that higher expression of XRCC4 was associated with worse 
locoregional control of hypopharyngeal cancer by radiotherapy [25]. We also found that 
high expression of XRCC4 was an indicator of poor OS in patients with esophageal 
cancer [26] or uterine cervical cancer [27]. To prevent IBTR in patients with high XRCC4 
expression, additional treatment such as boost irradiation may be considered or 
mastectomy might be selected instead of breast-conserving therapy. 
  In the present study, XRCC4 expression was significantly higher in the TR group than 
the non-IBTR group, whereas the NP group showed no significant difference from the 
non-IBTR group (Fig. 3C). TR was significantly more frequent among patients with high 
XRCC4 expression by tumor cells than among those with low XRCC4 expression, 
whereas XRCC4 expression was not significantly related to NP (Figs. 3C and 3D). 
Among various biological, clinical, and treatment-related factors, XRCC4 expression was 
the only significant determinant of TR in both univariate and multivariate analyses (Table 
4). These results suggest that high XRCC4 expression could be a specific indicator of TR. 
That is, TR may occur due to low radiosensitivity of tumor cells, which may possibly be 
related to high expression of XRCC4 expression, and prevention of IBTR by boost 
irradiation could be more effective against TR than NP. Our findings could contribute to 
individualization of radiation therapy for breast cancer based on XRCC4 expression.  
Some limitations of this study should be considered. It was based on retrospective data, 
so that, despite patient matching, some differences between the 2 treatment modalities 
may still exist. Furthermore, there was a difference of ER expression between IBTR and 
non-IBTR patients in the original cohort, but the background of non IBTR patients used 
in the matched analysis was different from that of original cohort (since they 
corresponded to the IBTR group). However, our finding that NHEJ-related proteins may 
be associated with IBTR regardless of ER expression seems to be important and suggests 
that IBTR could be prevented by modifying radiotherapy according to XRCC4 expression. 


































































significantly higher frequency of IBTR than low XRCC4 expression. TR was 
significantly more frequent in patients with high XRCC4 expression than in patients with 
low XRCC4 expression. However, XRCC4 expression by tumor cells was not 
significantly associated with NP. Similar results were obtained by both univariate analysis 
and multivariate analysis. TR may occur because of the low radiosensitivity of tumor 
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Figure 1  
(A)  Ipsilateral breast tumor relapse (IBTR)-free rate for the original cohort (n=560).  
(B) (C)  
Comparison of IBTR-free rate (B) and overall survival rate (C) of true recurrence versus new primary. 
 
Figure 2 
(A) Expressions of Ku70, and XRCC4 in breast cancer cells in biopsy specimens. Original 
magnification was × 400.   
(B) (C) 
Comparison of expression of XRCC4 (B) and Ku70 (C) in tumor tissues of non-IBTR, True 




IBTR-free survival rates stratified according to XRCC4 (A) and Ku70 (B) expression in the 
propensity- score matched-pair cohort (n=120). 
(C)(D)  
Incidence-free rates for True Recurrence (C) and New Primary (D) stratified according to XRCC4 







































































Table 1  Patient and treatment characteristics of the original cohort (n = 560). 
        n                     (%) 
Median age (range)    50  (24 - 79) 
Clinical T stage 
   Tis                                      29                      (5.2) 
     T1                                       420   (75.0) 
T2                                       72   (12.6) 
     T3                                       2   (0.4) 
unknown                                38   (6.8) 
Histology of index tumor 
       Invasive ductal carcinoma   476           (85.0) 
       Invasive lobular carcinoma                7   (1.3) 
       Noninvasive ductal carcinoma             26   (4.6) 
       Others                  51   (9.1) 
Lymphovascular invasion                         
       Absent                                  251   (44.8) 
       Present                                  301   (53.8) 
       unknown     8   (1.4) 
Nodal metastasis 
Absent  480                     (85.7) 
Present                                  80                      (14.3) 
Margin 
       Negative                    433   (94.1) 
       Positive     127   (5.9) 
Estrogen receptor status     
Negative     156   (27.9) 
Positive     374   (66.8) 
unknown     30   (5.3) 
Endocrine therapy 
       No      155   (27.7) 
       Yes                                      405   (72.3) 
Chemotherapy 
No     452   (80.7) 
Yes                                      108   (19.3) 
Radiation 
       Median dose (range)   50  (48-60) 
       Boost 
         No     433   (77.3) 
         Yes     127   (20.7) 
    Supraclavicular node irradiation   
       No     480   (85.7) 
       Yes     80   (14.3) 
Table 2  Clinical characteristics of True Recurrence and New Primary 
                                    True Recurrence    New Primary      P value 
                                        (n=22)            (n=18)     
Age                      0.360    
  <50      10      11 
  50      12      7 
Histology of index tumor         0.0503 
  Invasive ductal carcinoma           17      15              
  Invasive lobular carcinoma           1      0               
  Noninvasive ductal carcinoma        4      0               
  Others                     0                 3               
Lymphovascular invasion                                                0.516 
  Absent                              10      10 
  Present                             12             8 
Margin           0.731 
      Negative                     17      13 
      Positive             5      5 
Estrogen receptor status            1.000 
Negative      13      10 
Positive             9      7 
Endocrine therapy          0.751 
      No      12      10      
      Yes      10      10 
Chemotherapy          0.731 
No      17      13 
Yes                                 5      5     
Boost           0.731 
 No      17      13 
      Yes      5      5 
Supraclavicular node irradiation        0.427 
      No      17        16 
      Yes      5      2 
  
Table 3  
Impact of clinical prognostic variables on IBTR free survival for the original cohort by 
univariate and multivariate analysis 
                                                                           IBTR 
Parameter                                        Hazard ratio       95% CI         P value   
Univariate 
Age ( 50 vs 50)     0.899          0.482-1.685  0.736 
Histology of index tumor                           1.055          0.954-1.167  0.297 
(invasive ductal/lobular vs noninvasive/others) 
Lymphovascular invasion (absent vs present)  0.871         0.468-1.620  0.663 
Estrogen receptor status (negative vs positive) 0.306        0.161-0.581  <0.001* 
Chemotherapy (no vs yes)    1.496        0.731-3.063  0.270 
  Boost (no vs yes)     1.214        0.589-2.502  0.600 
      Supraclavicular irradiation (no vs yes)  1.331        0.587-3.018  0.493 
 
Multivariate 
Age ( 50 vs 50)     1.051        0.553-1.996  0.879 
Histology of index tumor    1.067        0.961-1.185  0.227 
(invasive ductal/lobular vs noninvasive/others) 
Lymphovascular invasion (absent vs present)  0.824        0.441-1.540  0.543 
Estrogen receptor status (negative vs positive) 0.290        0.152-0.552  <0.001* 
Boost (no vs yes)     1.169        0.555-2.461  0.682 
 Abbreviations: IBTR = Ipsilateral breast tumor relapse, CI = confidence interval 
  
Table 4 
 Patient and treatment characteristics of IBTR cohort and the matched-pair cohort. 
                                         IBTR           Control           P value 
                                         (n=40)           (n=80)     
Age                        0.697    
     <50      30      46 
     50      10      34 
Histology of index tumor                                1.000 
     Invasive ductal carcinoma           32      64              
     Invasive lobular carcinoma            1      2               
     Noninvasive ductal carcinoma   4      7               
     Others (special types)    3                 7               
Lymphovascular invasion                                                 1.000 
     Absent      20      41 
     Present      20             39 
Margin            1.000 
     Negative                      30      59 
     Positive             10      21 
Estrogen receptor status             1.000 
Negative      24      48 
Positive             16      32 
Chemotherapy           1.000 
No       30      61 
Yes                                  10      19     
Boost            1.000 
 No       30      59 
     Yes      10      21 
Supraclavicular node irradiation         1.000 
     No       33        66 
     Yes      7      14 
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